iBio, Inc. IBIO 深 滬
已收盤 10-24 16:00:00 美东时间
1.21
-0.060
-4.72%
華盛通- 最 高1.27
- 今 開1.26
- 成交量 425.38万股
- 最 低 1.14
- 昨 收 1.27
- 總市值 1998.84万
- 52周最高 6.8908
- 市盈率 靜 --
- 換手率 0.03%
- 52周最低 0.5562
- 委 比 11.26%
- 總股本 1651.93万
- 歷史最高 17400.00
- 量 比 0.17
- 振 幅 10.24%
- 歷史最低 0.5562
- 每 手 1
- 風險率 1.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Why Did iBio Shares Surge Over 11% In Pre-Market Trading?
iBio shares rose sharply after announcing upcoming presentations on its obesity treatment candidate at two industry conferences.
10-23 16:07
Intelligent Bio Solutions Secures Major UK Contract with Multinational Industrial Service Provider
Intelligent Bio Solutions Inc. (INBS) has secured a major contract with one of the UK's largest industrial service providers, marking a significant UK deployment of its rapid, non-invasive drug testing technology. The customer, a global leader in energy, defense, and industrial sectors, employs over 30,000 staff worldwide and 3,000 within the UK and Ireland. Transitioning from traditional urine-based testing, the company expects faster, cleaner, ...
10-23 12:30
iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
iBio, Inc. (NASDAQ: IBIO), an AI-driven precision antibody therapies innovator, announced its participation in the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, November 10–12, 2025. CEO Martin Brenner will discuss the company's progress in becoming a clinical-stage biotech and its next-generation obesity pipeline in a fireside chat on November 10 at 8:30 a.m. ET. CFO Felipe Duran will also attend for one-on-one meetings. A li...
10-23 11:00
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025
iBio, Inc. announced that two of its executives will present at upcoming conferences. Cory Schwartz will discuss the Activin E antibody, IBIO-610, at ObesityWeek 2025, while Martin Brenner will present at PEGS Europe 2025. IBIO-610 has shown potential for fat-selective weight loss and enhancing GLP-1 therapies. The company focuses on developing precision antibody therapies for cardiometabolic diseases and obesity using AI-driven platforms.
10-21 11:00
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers iBio (NASDAQ:IBIO) stock increased by 28.8% to $1.15 during Monday's a...
10-21 05:08
美股大行评级 | 潜在最高涨幅37.45%，甲骨文获多家机构上调目标价；瑞穗上调美光科技目标价升至240美元
今日重点评级关注：韦德布什：维持Artiva Biotherapeutics"跑赢大市"评级，目标价从18美元升至23美元；巴克莱：维持Cellectis"超配"评级，目标价从4美元升至8美元
10-20 10:03
Leerink Partners Initiates Coverage On iBio with Outperform Rating, Announces Price Target of $2
Leerink Partners analyst Roanna Ruiz initiates coverage on iBio (NASDAQ:IBIO) with a Outperform rating and announces Price Target of $2.
10-17 19:47
iBio, Inc. Reports Transformative Fiscal Year 2025
Ibio Inc ( ($IBIO) ) has released its Q4 earnings. Here is a breakdown of the i...
09-06 11:54
Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Shares of Serina Therapeutics Inc (NYSE:SER) rose sharply in pre-market trading...
08-26 17:52
